Ischemic Cerebral InfarctionPhase 3ORISNCT07242599
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
A Phase 3 study testing High target group and Low target group in people with Ischemic Cerebral Infarction, run by Beijing Tiantan Hospital at 199 sites in China.
Trial summary
The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C < 1.4 mmol/L). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Cerebral Infarction
- What is being tested?
- High target group and Low target group
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,810 participants
- Where
- 199 sitesChina
- Study dates
- 22 Apr 2026to 1 Apr 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Obtaining informed consent;
- Age ≥18 years;
- Patients with ischemic stroke within 3 months( NIHSS<15 before randomization);
- Presence of ≥50% stenosis in major intracranial or extracranial arteries, and related to the symptoms of the current episode or the location of infarction;
- LDL-C ≥ 70 mg/dL (1.8 mmol/L) at screening.
Who cannot join
- History of cerebral hemorrhage at any time (microhemorrhages present only on SWI are not an exclusion criterion)
- Hemorrhage or other pathological neurological conditions on baseline brain CT/MRI (e.g., vascular malformations, tumors, abscesses, or common non-ischemic brain diseases like multiple sclerosis);
- Presence of isolated sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness or vertigo, but no evidence of recent infarction on baseline head CT or MRI;
- Unable to complete the assessment of intracranial and extracranial arterial stenosis before randomization
- mRS score≥2 before onset (based on assessment of medical history);
- Stroke caused by angioplasty/vascular surgery;
Show all 20Show fewer
- Cardioembolic stroke caused by atrial fibrillation, artificial heart valves, endocarditis, mitral stenosis, sinus node dysfunction, etc.
- Most recent fasting triglycerides >400 mg/dL (4.5 mmol/L) prior to randomization;
- Uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg);
- Hypothyroidism diagnosed within 1 month before randomization.
- Severe renal impairment (eGFR <30 mL/min/1.73m²);
- Active liver disease or dysfunction (AST/ALT >3×ULN within 30 days pre-randomization);
- NYHA Class III/IV heart failure within 1 year prior to randomization;
- Life-limiting non-cardiovascular diseases (life expectancy <1 years);
- Malignancy within 10 years (excluding adequately treated basal cell carcinoma, cervical CIS, DCIS, or stage 1 prostate cancer);
- Known hypersensitivity to monoclonal antibody therapies;
- PCSK9 inhibitor use within 3 months before randomization.
- Participation in other drug/device trials within 30 days;
- Women of childbearing potential without contraception, pregnancy, or lactation;
- Inability to understand or comply with the study due to mental illness, cognitive, or emotional disorders, or other reasons deemed unsuitable for participation in the study by the investigator.
Trial locations and contacts
199 sites in 1 country. Contact the study team or a site near you to ask about taking part.
199 sites in 1 country
China199 sites
Puding County People's Hospital
Anshun, Guizhou, 562100
Yunfei Zhao, 18585890623, 18585890623@wo.cn
Baise City People's Hospital
Baise City, Guangxi, 533099
Shaofa Li, 13977693812, lishaofa88@sina.com
Affiliated Hospital of Hebei University
Baoding, Hebei, 071000
Weiying Di, 13931239834, diweiying@126.com
Hebei Tang County People's Hospital
Baoding, Hebei, 071030
Chunyu Di, 15081246655, 15081246655@139.com
The No.2 Hospital Of Baoding
Baoding, Hebei, 071051
Fengli Zhao, 17732288689, fenglizhaovip@163.com
Baotou City Central Hospital
Baotou, Inner Mongolia, 014040
Yu Fan, 13654729916, 13654729916@163.com
Sinopharm North Hospital
Baotou, Inner Mongolia, 221116
Min Wang, 13474986532, bfyysjnkwm@163.com
Bayannur Hospital
Bayan Nur, Inner Mongolia, 015000
Wen Gao, 17604788171, 122805722@qq.com
Wuyuan County People's Hospital
Bayan Nur, Inner Mongolia, 015100
Yongming Chen, 15647811211, cyongm2010@163.com
The First Hospital of Fangshan District, Beijing
Beijing, Beijing Municipality, 102499
Jianhua Li, 13552375686, lijianhua19730521@163.com
Beijing Tiantan Hospital, Capital Medical University
Beijing
Yongjun Wang, MD, +86 13911172565, yongjunwang111@aliyun.com
Liye Dai, MD, +86 15010545290, yezidailiye@163.com
General Hospital of Benxi Iron
Benxi, Liaoning, 117000
Hang Zhao, 18041440349, zhaohang75@163.com
Benxi Central Hospital
Benxi, Liaoning, 117100
Chengguang Song, 15041488936, scg2011@163.com
Yangxin County People's Hospital
Binzhou, Shandong, 251800
Jishuang Kang, 18054566072, yxkangjs123@163.com
Binzhou Medical University Hospital
Binzhou, Shandong, 256603
Wenbin Ma, 13615438722, mawbin@163.com
China-Japan Union Hospital of Jilin University
Changchun, Jilin, 130033
Ying Xing, 13844021603, xingying1970@163.com
Taoyuan People'S Hospital
Changde, Hunan, 415700
Jing Lei, 13787887931, 419136036@qq.com
Liuyang Jili Hospital
Changsha, Hunan, 410399
Yuzhang Bei, 13487494488, 277475748@qq.com
Changzhi People's Hospital
Changzhi, Shanxi, 046000
Bingxia Li, 15035501050, llbbxx2001@126.com
Chenzhou 3rd People's Hospital
Chenzhou, Hunan, 423000
Huixiang Tang, 13487867548, 2277024052@qq.com
Chenzhou No.1 People's Hospital
Chenzhou, Hunan, 423099
Xiaoxi Yao, 13637353120, yaoxxtt@126.com
Affiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, 024000
Weili Zhao, 13948162665, wlzhao1968@163.com
Chifeng Hospital of Traditional Chinese and Mongolian Medicine
Chifeng, Inner Mongolia, 024005
Guozhi Lu, 13722169555, gz9555@sina.com
Chifeng City Center Hospital Ningcheng County
Chifeng, Inner Mongolia, 024200
Lijuan Dou, 13739934271, 441855613@qq.com
Ningcheng County Hospital of Traditional Chinese and Mongolian Medicine
Chifeng, Inner Mongolia, 024200
Yanqing Bai, 13840961618, yanqing_006@163.com
Chongqing Sanbo Changan Hospital
Chongqing, Chongqing Municipality, 400023
Mingli Chen, 18502377051, 836985160@qq.com
The Fifth People's Hospital of Chongqing
Chongqing, Chongqing Municipality, 400062
Ge Jin, 15123202128, wysnjg@163.com
The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College
Chongqing, Chongqing Municipality, 401334
Hao Xie, 13594687518, 574209771@qq.com
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Dalian, Liaoning, 116000
Hongling Zhao, 13998515718, zhaohongling2000@126.com
The first affiliated hospital of Dalian Medical University
Dalian, Liaoning, 116011
Bingwei Zhang, 18098876286, zhangbingweidoc@163.com
Dalian University Affiliated Xinhua Hospital
Dalian, Liaoning, 116021
Yi Wang, 13019455197, wangyi226626@sina.com
Dalian lvshunkou district traditional Chinese medicine hospital
Dalian, Liaoning, 116041
Changhao Jiang, 18640937766, jiangchanghao2@163.com
Dalian Jinzhou District First People's Hospital
Dalian, Liaoning, 116199
Huijuan Sun, 18018902263, sunhuijuan71@163.com
Wafangdian Third Hospital Co., Ltd.
Dalian, Liaoning, 116300
Xingguo Jiang, 15164091312, 174983596@qq.com
Dandong Central Hospital
Dandong, Liaoning, 118000
Cheng Bi, 15841587837, 15841587837@163.com
Dandong First Hospital
Dandong, Liaoning, 118000
Lishu Wan, 13591528175, wanwan0409@163.com
Daqing No.4 hospital
Daqing, Heilongjiang, 163000
Yanhui Wang, 13159995858, 1636522400@qq.com
Daqing Oilfield General Hospital
Daqing, Heilongjiang, 163001
Xuhai Gong, 13349491212, 903211995@qq.com
DA QING LongNan Hospital
Daqing, Heilongjiang, 163453
Kai Hui, 13059043677, huikai2007dq@sina.com
People's Hospital of Qihe County
Dezhou, Shandong, 251100
Haitao Li, 13869215737, userfiled@126.com
Ningjin People's Hospital
Dezhou, Shandong, 253499
Chunjie Yang, 13869268655, yangchunjie@yeah.net
Minxian County Hospital of Traditional Chinese Medicine
Dingxi, Gansu, 748400
Zhixiang Liu, 13679324242, 807851367@qq.com
The Second People's Hospital of Dongying
Dongying, Shandong, 257335
Chunlei Li, 13954693492, lichunlei1223@163.com
Liaoning Health Industry Group Fukuang General Hospital
Fushun, Liaoning, 113008
Hong Zhang, 15694136301, zhanghong429@163.com
Fuyang People's Hospital
Fuyang, Anhui, 236004
Jinghong Lu, 13966839305, lujinghong2002@126.com
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, 570311
Bin Chen, 18489966998, hyefy12452@muhn.edu.cn
Cixian People's Hospital
Handan, Hebei, 056500
Jinhai Yan, 13930033143, Wuppcxrmyy2023@163.com
Weixian People's Hospital
Handan, Hebei, 056800
Xuekong Li, 13803290087, 1006519700@qq.com
HanDan Central Hospital
Handan, Hebei, 057150
Huiyong Huo, 18931038270, 1577228094@qq.com
Qiuxian County People's Hospital
Handan, Hebei, 057450
Xin Wang, 13832045118, qxyywx@163.com
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001
Di Zhong, 13766851510, dityan@163.com
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150086
Peifang Liu, 18004661136, liupeifang2299@163.com
Beian No.1 People's Hospital
Harbin, Heilongjiang, 164000
Kailu Sun, 18245677887, 137160874@qq.com
Hebi Coal Industry (Group) Co., Ltd. General Hospital
Hebi, Henan, 458031
Yanhua Zhang, 13939238229, hnhbzyh@163.com
No.1 People'S Hospital of Heihe
Heihe, Heilongjiang, 164300
Xuefei Liu, 18645663506, 3926231393@qq.com
Hejian People's Hospital
Hejian, Hebei, 062450
Dongqi Liu, 13700382558, 2543165501@qq.com
Hengshui People's Hospital
Hengshui, Hebei, 053000
Xiaoli Wang, 18633680078, hshywxl@163.com
The NO.4 People's Hospital of Hengshui
Hengshui, Hebei, 053000
Jianling Zhang, 13191905169, hstczjl@126.com
The NO.4 People's Hospital of Hengshui
Hengshui, Hebei, 053000
Jingwen Cui, 13292236603, zlh5176@163.com
Yuncheng County People's Hospital
Heze, Shandong, 274799
Guoqiang Yang, 15965855123, 12601830@qq.com
Tuoketuo County Hospital
Hohhot, Inner Mongolia, 010200
Youjun Liu, 13347128287, 117966323@qq.com
Lianshui County People's Hospital
Huai'an, Jiangsu, 223400
Yadong Yu, 15952336789, Ls_yyd@163.com
Huizhou First Hospital
Huizhou, Guangdong, 516003
Chunsheng Cai, 15819870919, uksung@163.com
Huidong People'S Hospital
Huizhou, Guangdong, 516300
Tingna Zhu, 18933541720, 184867592@qq.com
Huludao Central Hospital
Huludao, Liaoning, 125001
Changming Xu, 15382008866, zxyyxcm_hld@163.com
HuZhou Central Hospital
Huzhou, Zhejiang, 313000
Bing Zhang, 13705723721, sjnkhz@163.com
The First Affiliated Hospital of Jiamusi University
Jiamusi, Heilongjiang, 154000
Yuling Jin, 15694548223, 975795903@qq.com
The Hongda Hospital of Jiamusi University
Jiamusi, Heilongjiang, 154000
Changsi Ai, 19845080777, 61834444@qq.com
Jiaozuo Coal Mining Group Co., Ltd. Central Hospital
Jiaozuo, Henan, 454001
Dongyun Chen, 13938198933, zhennyan@126.com
The First Affiliated Hospital of Henan Polytechnic University (Jiaozuo Second People's Hospital)
Jiaozuo, Henan, 454001
Zhenyu Kong, 15239110006, ysynkzy@126.com
Xiuwu County People's Hospital
Jiaozuo, Henan, 454350
Guangming Kang, 13938146566, 51060276@qq.com
Qinyang City Hospital of Traditional Chinese Medicine
Jiaozuo, Henan, 454550
Gongping Zhu, 13782701968, zgp2@126.com
Qinyang People's Hospital
Jiaozuo, Henan, 454550
Jiafeng Dong, 15939165367, 857844084@qq.com
Mengzhou Fuxing hospital
Jiaozuo, Henan, 454750
Dali Li, 13938140266, drlidali@163.com
Mengzhou Hospital of Traditional Chinese Medicine
Jiaozuo, Henan, 454750
Baoguo Xue, 13569165207, xuebg123@sohu.com
Haiyan People's Hospital
Jiaxing, Zhejiang, 314399
Zhenhua Xi, 13819069729, sj-xizh@163.com
The First People's Hospital of Jingdezhen
Jingdezhen, Jiangxi, 333099
Minghua Cao, 13979881026, xiongfushui@126.com
Qufu People's Hospital
Jining, Shandong, 273100
Huijie Sun, 15265750190, shenqiaoqi1988@126.com
Jiujiang No.1 People's Hospital
Jiujiang, Jiangxi, 332000
Hongbing Nie, 13607927780, niehongbin1@126.com
Shanghai General Hospital Jiuquan Hospital
Jiuquan, Gansu, 735008
Baihai Guo, 13830156690, 908137952@qq.com
Mudanjiang Hospital of Beidahuang Group
Jixi, Heilongjiang, 158300
Chuanbao Yu, 15846446677, msyuchuanbao@163.com
Jiyuan Hospital of Traditional Chinese Medicine
Jiyuan, Henan, 459001
Hongqin Yang, 13938170576, yhq19720828@126.com
The People's Hospital of the Qiandongnan Miao and Dong Autonomous Prefecture
Kaili, Guizhou, 556099
Xiaosong Li, 13312448228, 2575051958@qq.com
Gansu Provincial Maternity and Child-care Hospital(Gansu Provincial Central Hospital)
Lanzhou, Gansu, 730070
Rong Yin, 13919930466, yin_rong_@163.com
The First People's Hospital of Yuzhong County
Lanzhou, Gansu, 730100
Xiaopo Shen, 18153988002, silencesxp@163.com
Liaocheng Brain Hospital
Liaocheng, Shandong, 252000
Xinbo Zhuang, 13346258600, 10692996@qq.com
Liaocheng City Central Hospital
Liaocheng, Shandong, 252001
Xiting Zhang, 18063559551, 2844168014@qq.com
The Third People Hospital in Liaocheng
Liaocheng, Shandong, 252006
Bo Feng, 18563528510, 47702306@qq.com
Liaocheng People's Hospital
Liaocheng, Shandong, 252037
Dong Guo, 13396258699, guodonglc8699@163.com
The people's Hospital of Linqing
Liaocheng, Shandong, 252699
Wei Zhang, 13563532266, 13563532266@126.com
The People's Hospital of Gaotang
Liaocheng, Shandong, 252899
Chunlei Zhang, 13869543363, 13396258808@189.cn
Linfen Central Hospital
Linfen, Shanxi, 041000
Hongguo Dai, 15935767592, daihongguo3199@163.com
Lishui Central Hospital
Lishui, Zhejiang, 323000
Xiao Peng, 13626783639, pengxiao2508@163.com
Liuzhou Worker's Hospital
Liuzhou, Guangxi, 545005
Liya Pan, 13977250101, Panlya@126.com
Lianyuan People's Hospital
Loudi, Hunan, 417100
Yiyong Zhang, 13975782626, zhang81520@qq.com
Luoyang First People's Hospital
Luoyang, Henan, 471002
Jinfeng Shi, 13633871485, 540715474@qq.com
Luoyang Central Hospital
Luoyang, Henan, 471009
Zhihui Duan, 18537919198, duanzhihui76@126.com
The Second Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 471099
Yaliang Yu, 15225590136, 406356708@qq.com
Meihekou Central Hospital
Meihekou, Jilin, 135000
Rui Wang, 15114379494, wangrui2323@163.com
Meishan Cardio Cerebrovascular Disease Hospital
Meishan, Sichuan, 062000
Junyan Zeng, 18391807268, 383558826@qq.com
People'S Hospital of Tanghe
Nanyang, Henan, 473400
Minqiang Qu, 13683909120, 404768751@qq.com
Ningde People's Hospital
Ningde, Fujian, 352100
Guoping Zou, 13850326351, zoug-ping@163.com
The People's Hospital of Nujiang Lisu Autonomous Prefecture
Nujiang, Yunnan, 673299
Liqin He, 13988678392, hlq6932@126.com
Pingdingshan The second people's hospital
Pingdingshan, Henan, 467000
Yankuo Wang, 15637582390, wyk94@126.com
The First People's Hospital of Pingdingshan
Pingdingshan, Henan, 467099
Hongxu Wang, 13303756971, 42242085@qq.com
Ninger People's Hospital
Pu'er, Yunnan, 665199
Junyong Zhao, 18108791218, 18108791218@163.com
Chinese Medicine Hospital Of Puyang
Puyang, Henan, 457000
Ruili Liu, 17698298178, liuliu1982@163.com
Puyang Oilfield General Hospital
Puyang, Henan, 457000
Yutie Zhao, 13633935069, 3785873340@qq.com
Puyang People's Hospital
Puyang, Henan, 457000
Jintao Guo, 18639399652, gjt369@126.com
Puyang County People's Hospital
Puyang, Henan, 457161
Sumin Bai, 18538335396, 309589341@qq.com
Nanle People's Hospital
Puyang, Henan, 457400
Tingting Zhang, 13503930546, 1024675614@qq.com
Qingdao Cardiovascular Hospital Co., Ltd.
Qingdao, Shandong, 266000
Shiyao You, 18660298128, 285751500@qq.com
Tianjin Cancer Hospital Qinhuangdao Branch
Qinhuangdao, Hebei, 066002
Hongmei Zhang, 18133858389, zhmzhongguo@126.com
The Second Hospital of Qinhuangdao
Qinhuangdao, Hebei, 066699
Guanglei Li, 13613355378, liguanglei123@126.com
The Second Affiliated Hospital of Qiqihar Medical University
Qiqihar, Heilongjiang, 161000
Hongjiao Wang, 13946267867, aj.wang@163.com
Sanmenxia Central Hospital
Sanmenxia, Henan, 472000
Shufang Yao, 15138163911, yaoshufang2008@126.com
Yellow River Sanmenxia Hospital
Sanmenxia, Henan, 472000
Meng Xue, 15039875526, 531897034@qq.com
The First People Hospital of Lingbao
Sanmenxia, Henan, 472599
Wei Wu, 15839824116, 1034881652@qq.com
Liqun Hospital, Putuo District, Shanghai
Shanghai, Shanghai Municipality, 200333
Zongyan Dang, 15000988298, dzygsjc@163.com
Shanghai Fourth People's Hospital, Affiliated to Tongji University
Shanghai, Shanghai Municipality, 200434
Yibin Fang, 13585831041, fangyibin@vip.163.com
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 201999
Jianren Liu, 18616341023, liujr021@sjtu.edu.cn
Shang Qiu Hospital of Tcm
Shangqiu, Henan, 476000
Zhenggao Chen, 15836819086, 525539124@qq.com
People's hospital of NingLing
Shangqiu, Henan, 476700
Zhixiang Sui, 13849674499, 2576308695@qq.com
Sui county traditional Chinese medicine hospital
Shangqiu, Henan, 476999
Ying Li, 13619878828, 1074317027@qq.com
Yugan Xinjiang hospital
Shangrao, Jiangxi, 335100
Fangqi Tian, 15390771678, tfq_01@163.com
Shaoguan Qujiang District People's Hospital
Shaoguan, Guangdong, 512100
Cai Zhang, 19866502028, 436028359@qq.com
Shaoxing people's hospital
Shaoxing, Zhejiang, 312000
Yanxing Zhang, 13867557652, auwxf01@163.com
Shenmu Hospital
Shenmu, Shaanxi, 719300
Shengli Sun, 13379329868, 729833865@qq.com
Northern Theater Command General Hospital
Shenyang, Liaoning, 110016
Huisheng Chen, 13149807172, chszh@aliyun.com
Central Hospital Affiliated to Shenyang Medical College
Shenyang, Liaoning, 110024
Runhui Li, 18002477116, llirh710717@163.com
The First People's Hospital Of Shenyang
Shenyang, Liaoning, 110041
Li Li, 13840247222, Lily720823@163.com
Northern Theater Command Air Force Hospital
Shenyang, Liaoning, 110042
Jing Wang, 13322445060, hbf44132@163.com
The People's Hospital of Liaoning Province
Shenyang, Liaoning, 110067
Muhui Lin, 17702485111, lcllmh@126.com
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000
Junli Zhen, 13831129670, zhenjunli666@163.com
Xingtang County People's Hospital
Shijiazhuang, Hebei, 050699
Yanxin Wang, 18633876653, bdaczfg@163.com
Xinji Traditional Chinese Medicine Hospital
Shijiazhuang, Hebei, 052360
Yunsi Cao, 15176953979, ssyycc234@sina.com
The Fifth People's Hospital of Ningxia
Shizuishan, Ningxia, 753000
Jiqin Yang, 13895329070, 61993234@qq.com
The third hospital of shi zui shan
Shizuishan, Ningxia, 753400
Juyan Zhang, 18152525995, 791322187@qq.com
Hongxinglong Hospital of Beidahuang Group
Shuangyashan, Heilongjiang, 155811
Degang Sun, 13329334216, 13329334216@163.com
Grand Hospital of Shuozhou
Shuozhou, Shanxi, 036002
Guan Wei, 13734210694, 307543402@qq.com
Siping City Central People's Hospital
Siping, Jilin, 136099
Junfeng Zhao, 13843443119, jlspzjf2727@163.com
Suining Center Hospital
Suining, Sichuan, 629099
Wenli Xing, 19911866140, 39280847@qq.com
Siyang Kangda Hospital
Suqian, Jiangsu, 223798
Yanan Zhu, 18936900826, happyzhuyanan@163.com
The Second Affiliated Hospital of Shandong First Medical University
Tai’an, Shandong, 271099
Haitao Wang, 18553879291, docwht@163.com
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001
Junhong Guo, 13753127070, neuroguo@163.com
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001
Zhanjin Deng, 13513639627, 13513639627@163.com
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, 030024
Chen Chen, 13934161870, 13934161870@163.com
Guye District Hospital of Traditional Chinese Medicine, Tangshan
Tangshan, Hebei, 063199
Xiangjun Ji, 15933400014, 469003666@qq.com
Yutian County Hospital of Traditional Chinese Medicine
Tangshan, Hebei, 064199
Zhiwei Song, 13731528056, szwdeyx@126.com
First People's Hospital of Tianshui
Tianshui, Gansu, 741000
Guoping Ma, 13919660919, maguopingdr@163.com
The First Hospital of Xifeng County
Tieling, Liaoning, 112400
Rui Zhang, 13624104199, 6861441@qq.com
Tonghua Dongchang District People's Hospital
Tonghua, Jilin, 134001
Zhiquan Zhu, 15143596655, 490584871@qq.com
Tongliao People's Hospital
Tongliao, Inner Mongolia, 028000
Shuyao Wang, 13848555690, 15653292@qq.com
Tongren People's Hospital
Tongren, Guizhou, 554300
Long Liao, 15121644332, 1992500431@qq.com
Xinjiang Production&Construaction Corps Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, 830002
Yan Liu, 15292409455, liuyan_333@126.com
Weifang People's Hospital
Weifang, Shandong, 261000
Li Zhou, 13869621818, weifangzhou003@163.com
People's Hospital of Gaomi
Weifang, Shandong, 261500
Quanhao Li, 13721968559, liquanhao120@sina.com
People's Hospital of Changle County
Weifang, Shandong, 262400
Feng Fen, 13573682667, 1013830768@qq.com
Weihai Central Hospital
Weihai, Shandong, 264400
Xia Zhan, 18306305637, wdzhx686@sina.com
Weihai Central Hospital
Weihai, Shandong, 264400
Honghao Man, 18306300858, manhonghao1@163.com
Weihai Wendeng District People's Hospital
Weihai, Shandong, 264499
Jinguo Zhao, 13561852177, zjg52177@163.com
Department of Yongjia People's Hospital
Wenzhou, Zhejiang, 325100
Han Yu, 13616621974, han21974@126.com
Affiliated Yueqing Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325600
Saizhen Wu, 13757789268, wusaizhen@163.com
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071
Bin Mei, 13037196699, neuromei20@163.com
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, 241001
Zhiming Zhou, 13966019211, Neuro_depar@hotmail.com
Xi 'an Fengcheng Hospital
Xi'an, Shaanxi, 710016
Aimei Wu, 13319207439, 13319207439@163.com
The Second Affiliated Hospital of Xi'an Medical University
Xi'an, Shaanxi, 710038
Qi Zhou, 15902926849, zhouqi939@163.com
Xianning Central Hospital
Xianning, Hubei, 437000
Jie Du, 15272730557, 20106452@qq.com
Xingtai central hospital
Xingtai, Hebei, 054000
Yongmei Kong, 13603193670, xtsykym@126.com
Xingtai People's Hospital
Xingtai, Hebei, 054001
Xipeng Li, 13932916969, lxp731221@163.com
Weixian People's Hospital
Xingtai, Hebei, 054700
Zhenlin Wang, 15383196218, sunzhengyishi@126.com
Qinghe people's hospital
Xingtai, Hebei, 054899
Yingzhuo Zang, 13223268969, wangzang2008@sina.com
Qinghai Provincial Traffic Hospital
Xining, Qinghai, 810000
Jinlei Zhu, 13997289117, 13997289117@163.com
The First Affiliated Hospital of Henan Medical University
Xinxiang, Henan, 453100
Jianhua Zhao, 13803800541, 051092@xxmu.edu.cn
People's Hospital of Xixian
Xinyang, Henan, 464399
Ruiyi Wang, 15137600760, wry15137600760@163.com
Changge People's Hospital
Xuchang, Henan, 461500
Gexia Liu, 13503899368, m13903992308@163.com
Inner Mongolia Forestry General Hospital
Yakeshi, Inner Mongolia, 022150
Jing Wang, 13947002639, Wj5667mail@163.com
Zichang People's Hospital
Yan’an, Shaanxi, 717399
Runting Jing, 13891139790, 250711302@qq.com
The First People's Hospital of Yangquan
Yangquan, Shanxi, 045000
Jiabin Zhao, 13994470191, 1436660584@qq.com
Yantai Hospital of Traditional Chinese Medicine
Yantai, Shandong, 264000
Lin Sun, 15953554077, ytzyysl@163.com
YEDA hospital
Yantai, Shandong, 264006
Haihui Luan, 15264551600, haihuiluan@163.com
Yantai Yuhuangding Hospital
Yantai, Shandong, 264099
Zhigang Liang, 13723987720, zgliang@hotmail.com
Yantai Taocun Central Hospital
Yantai, Shandong, 265301
Zhihua Hao, 13012563066, ythaozhihua@163.com
Qixia traditional Chinese medicine hospital
Yantai, Shandong, 265399
Xiaoyan Li, 13808915211, 1357612106@qq.com
Yantai Penglai traditional Chinese medicine hospital
Yantai, Shandong, 265699
Penglai Shi, 18953551266, 452405222@qq.com
Jiang'an County Hospital of Traditional Chinese Medicine
Yibin, Sichuan, 644200
Xiang Liu, 18408203949, 1027440878@qq.com
The Affiliated Hospital of Yongzhou Vocational and Technical College
Yongzhou, Hunan, 425199
Jie Yan, 18075812111, arnyyanjie@163.com
Zhalantun Hospital of Traditional Chinese and Mongolian Medicine
Zhalantun, Inner Mongolia, 162650
Chengyan Yang, 13948903839, y20080608@126.com
Zhalantun People's Hospital
Zhalantun, Inner Mongolia, 162650
Xiaoyu Qu, 17704705678, quxiaoyu2023@qq.com
Xuangang Hospital
Zhangjiakou, Hebei, 075199
Lina Qiao, 15031328157, 15031328157@163.com
Wuchuan People's Hospital
Zhanjiang, Guangdong, 524557
Guanrong Chen, 13543504754, 7161458@qq.com
Xingyang People's Hospital
Zhengzhou, Henan, 450199
Dongliang Yang, 15639730888, 824025309@qq.com
Xinmi Hospital of T.C.M
Zhengzhou, Henan, 452370
Jianmin Guo, 13938238698, kingguo0371@163.com
Zhoukou Yongshan Hospital
Zhoukou, Henan, 461300
Jinqi Fan, 18638083426, 765288157@qq.com
Taikang Xian People's Hospital
Zhoukou, Henan, 461499
Xinxia Zhao, 15890587206, 15890587206@139.com
The First People's Hospital of Zhumadian
Zhumadian, Henan, 463000
Xumei Li, 13513865177, 350029688@qq.com
Zhumadian Central Hospital
Zhumadian, Henan, 463000
Wanchun Li, 15713652696, 15713652696@163.com
The People's Hospital of Queshan County
Zhumadian, Henan, 463200
Jianxin Xu, 15978828086, 249957242@qq.com
The People's Hospital Of Biyang County
Zhumadian, Henan, 463799
Shuo Zhang, 17530350999, 84493071@qq.com
About this study
Official title: A Multicenter, Randomized, Open-label, Parallel-controlled, Event-driven, Blinded-endpoint Trial Evaluating the Efficacy and Safety of Ongericimab Injection in High-risk Stroke Patients With Intracranial or Extracranial Atherosclerotic Stenosis.
The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C < 1.4 mmol/L).
- Conditions
- Ischemic Cerebral Infarction
- Being tested
- High target group, Low target group
- Keywords
- ischemic stroke, lipid lowering therapy, Ongericimab Injection, LDL-C target
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High target groupCombination product
Standardized lipid-lowering therapy according to the Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases to achieve an LDL-C target below 70 mg/dL (1.8 mmol/L)
Low target groupCombination product
Ongericimab subcutaneous injection once every two weeks (150mg) or every four weeks(300mg) combined with standardized lipid-lowering therapy to achieve an LDL-C target below 55 mg/dL (1.4 mmol/L)
| Study group | Role | What they receive |
|---|---|---|
| Control group (High target group) | Active comparator | Standardized lipid-lowering therapy according to the Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases to achieve an LDL-C target below 70 mg/dL (1.8 mmol/L). Receives: Combination Product: High target group |
| Intervention group (Low target group) | Experimental | Ongericimab subcutaneous injection once every two weeks (150mg) or every four weeks(300mg) combined with standardized lipid-lowering therapy to achieve an LDL-C target below 55 mg/dL (1.4 mmol/L) Receives: Combination Product: Low target group |
What is being measured
The primary outcome is the main question the study is designed to answer.
The major cardiovascular events
The composite primary end point of major cardiovascular events includes ischemic stroke, myocardial infarction, death from cardiovascular causes.
Measured: A median of 2 years follow-up
Secondary outcomes (7)
New ischemic stroke
Ischemic stroke refers to acute focal cerebral or retinal infarction, excluding other non-ischemic causes, and meeting any of the following conditions: (1) clinical symptoms or imaging evidence of acute new focal neurological deficit lasting more than 24 hours; or (2) focal symptoms or signs lasting less than 24 hours, but with imaging evidence of new infarction; or (3) progression of pre-existing vascular ischemic stroke (i.e., NIHSS increase of ≥ 4 on the basis of the primary ischemic stroke, excluding hemorrhagic transformation after infarction or symptomatic intracranial hemorrhage) lasting more than 24 hours, with new ischemic changes on head MRI or CT.
Measured: A median follow-up of 2 years
Myocardial infarction
Measured: A median of 2 year follow-up
Vascular death
Measured: A median of 2 years follow-up
Poor functional prognosis (mRS score > 1) at 1 year
Measured: A median of 2 years follow-up
Severity of new stroke
Measured: A median of 2 years follow-up
Absolute and percent changes in LDL-C levels
Measured: A median of 2 years follow-up
Treatment-emergent serious adverse events (SAEs) and adverse events (AEs)
Treatment-emergent serious adverse events (SAEs) and adverse events (AEs) include cerebral hemorrhage, injection site infections, muscle-related adverse events, new-onset diabetes mellitus, and clinically significant laboratory abnormalities encompassing hepatic/renal function markers, creatine kinase (CK), fasting glucose, and glycated hemoglobin (HbA1c) during the double-blind treatment phase.
Measured: A median of 2 years follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start22 Apr 2026 (estimated)
- Primary completion1 Apr 2029 (estimated)
- Study completion1 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Ischemic Cerebral InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 4,810 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yongjun Wang, Beijing Tiantan Hospital
- Investigators
- Yongjun Wang, Principal investigator, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07242599
- Sponsor's protocol ID
- ORIS-2025-10
- Acronym
- ORIS
- Status last verified
- Mar 2026
- First submitted
- 17 Nov 2025
- Last updated
- 16 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
PubMed 21067804Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
PubMed 28304224Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
PubMed 26039521Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane B, Montgomery J, Chimowitz MI. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24;88(4):379-385. doi: 10.1212/WNL.0000000000003534. Epub 2016 Dec 21.
PubMed 28003500Shao C, Zhang S, Cheng Z, Yang K, Wang G, Shi X, Yang H, Ji Y, Li H, Zhang S, Ma J, Pei Z, Zhang Y, Li Y, Li L, Zheng Y, Shao C, Zhang M, Hao Y, Tang YD. Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial. Atherosclerosis. 2025 Aug;407:120408. doi: 10.1016/j.atherosclerosis.2025.120408. Epub 2025 Jun 16.
PubMed 40543299Lin J, Ji Y, Wang G, Ma X, Yao Z, Han X, Chen J, Chen J, Huang W, Xu G, Peng D, Yan P, Qiao P, He Y, Tang Y, Wang M, Zhang M, Yu J, Hao Y, Ma C. Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial. Atherosclerosis. 2025 Apr;403:119120. doi: 10.1016/j.atherosclerosis.2025.119120. Epub 2025 Jan 29.
PubMed 39999660Xu YY, Chen WQ, Wang MX, Pan YS, Li ZX, Liu LP, Zhao XQ, Wang YL, Li H, Wang YJ, Meng X; CNSR-III Investigators. Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III. BMJ Open. 2023 Mar 8;13(3):e069465. doi: 10.1136/bmjopen-2022-069465.
PubMed 36889830Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.
PubMed 21899409Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894.
PubMed 16899775Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavallee PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touze E, Varenne O, Vicaut E, Yelles N, Bruckert E; Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020 Jan 2;382(1):9. doi: 10.1056/NEJMoa1910355. Epub 2019 Nov 18.
PubMed 31738483
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Open-label, Parallel-controlled, Event-driven, Blinded-endpoint Trial Evaluating the Efficacy and Safety of Ongericimab Injection in High-risk Stroke Patients With Intracranial or Extracranial Atherosclerotic Stenosis.
- ClinicalTrials.gov ID
- NCT07242599
- Acronym / sponsor ID
- ORIS / ORIS-2025-10
- Conditions
- Ischemic Cerebral Infarction
- Keywords
- ischemic stroke, lipid lowering therapy, Ongericimab Injection, LDL-C target
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 4,810 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Study start
- 22 Apr 2026 (estimated)
- Primary completion
- 1 Apr 2029 (estimated)
- Study completion
- 1 Apr 2029 (estimated)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C < 1.4 mmol/L).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group (High target group) | Active comparator | Combination Product: High target groupStandardized lipid-lowering therapy according to the Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases to achieve an LDL-C target below 70 mg/dL (1.8 mmol/L). |
| Intervention group (Low target group) | Experimental | Combination Product: Low target groupOngericimab subcutaneous injection once every two weeks (150mg) or every four weeks(300mg) combined with standardized lipid-lowering therapy to achieve an LDL-C target below 55 mg/dL (1.4 mmol/L) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Obtaining informed consent;
- Age ≥18 years;
- Patients with ischemic stroke within 3 months( NIHSS<15 before randomization);
- Presence of ≥50% stenosis in major intracranial or extracranial arteries, and related to the symptoms of the current episode or the location of infarction;
- LDL-C ≥ 70 mg/dL (1.8 mmol/L) at screening.
Key exclusion criteria (20 listed)
- History of cerebral hemorrhage at any time (microhemorrhages present only on SWI are not an exclusion criterion)
- Hemorrhage or other pathological neurological conditions on baseline brain CT/MRI (e.g., vascular malformations, tumors, abscesses, or common non-ischemic brain diseases like multiple sclerosis);
- Presence of isolated sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness or vertigo, but no evidence of recent infarction on baseline head CT or MRI;
- Unable to complete the assessment of intracranial and extracranial arterial stenosis before randomization
- mRS score≥2 before onset (based on assessment of medical history);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High target groupStandardized lipid-lowering therapy according to the Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases to achieve an LDL-C target below 70 mg/dL (1.8 mmol/L) | Combination product | Control group (High target group) |
| Low target groupOngericimab subcutaneous injection once every two weeks (150mg) or every four weeks(300mg) combined with standardized lipid-lowering therapy to achieve an LDL-C target below 55 mg/dL (1.4 mmol/L) | Combination product | Intervention group (Low target group) |
Primary outcome
The major cardiovascular events
Time frame: A median of 2 years follow-up
The composite primary end point of major cardiovascular events includes ischemic stroke, myocardial infarction, death from cardiovascular causes.
7 secondary outcomes
New ischemic stroke
Time frame: A median follow-up of 2 years
Myocardial infarction
Time frame: A median of 2 year follow-up
Vascular death
Time frame: A median of 2 years follow-up
Poor functional prognosis (mRS score > 1) at 1 year
Time frame: A median of 2 years follow-up
Severity of new stroke
Time frame: A median of 2 years follow-up
Absolute and percent changes in LDL-C levels
Time frame: A median of 2 years follow-up
Treatment-emergent serious adverse events (SAEs) and adverse events (AEs)
Time frame: A median of 2 years follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Background: PubMed 21067804Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
- Background: PubMed 28304224Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Background: PubMed 26039521Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
- Background: PubMed 28003500Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane B, Montgomery J, Chimowitz MI. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24;88(4):379-385. doi: 10.1212/WNL.0000000000003534. Epub 2016 Dec 21.
- Results publication: PubMed 40543299Shao C, Zhang S, Cheng Z, Yang K, Wang G, Shi X, Yang H, Ji Y, Li H, Zhang S, Ma J, Pei Z, Zhang Y, Li Y, Li L, Zheng Y, Shao C, Zhang M, Hao Y, Tang YD. Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial. Atherosclerosis. 2025 Aug;407:120408. doi: 10.1016/j.atherosclerosis.2025.120408. Epub 2025 Jun 16.
- Results publication: PubMed 39999660Lin J, Ji Y, Wang G, Ma X, Yao Z, Han X, Chen J, Chen J, Huang W, Xu G, Peng D, Yan P, Qiao P, He Y, Tang Y, Wang M, Zhang M, Yu J, Hao Y, Ma C. Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial. Atherosclerosis. 2025 Apr;403:119120. doi: 10.1016/j.atherosclerosis.2025.119120. Epub 2025 Jan 29.
- Results publication: PubMed 36889830Xu YY, Chen WQ, Wang MX, Pan YS, Li ZX, Liu LP, Zhao XQ, Wang YL, Li H, Wang YJ, Meng X; CNSR-III Investigators. Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III. BMJ Open. 2023 Mar 8;13(3):e069465. doi: 10.1136/bmjopen-2022-069465.
- Results publication: PubMed 21899409Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.
- Results publication: PubMed 16899775Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894.
- Results publication: PubMed 31738483Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavallee PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touze E, Varenne O, Vicaut E, Yelles N, Bruckert E; Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020 Jan 2;382(1):9. doi: 10.1056/NEJMoa1910355. Epub 2019 Nov 18.
- Individual participant dataSharing planned: No
Related trials for Ischemic Cerebral Infarction
Recruiting
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Brainstem Stroke, ALS
Not yet recruitingPhase 3
Cilostazol for Prevention of Recurrent Stroke Trial
Stroke Recurrence, Myocardial Infarction
Not yet recruitingObservational study
Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients
Subarachnoid Hemorrhage, Aneurysmal, Brain Injuries, Traumatic
Not yet recruiting
Pilot Study to Determine the Optimal Protocol for Preoperative Transcutaneous Vagal Neurostimulation
Atrial Fibrillation (AF), Cerebral Vascular Accident (CVA)
RecruitingObservational study
Registry for CADASIL
Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yongjun Wang principal investigator
Beijing Tiantan Hospital
199 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing High target group and Low target group in people with Ischemic Cerebral Infarction, run by Beijing Tiantan Hospital at 199 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 199 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yongjun Wang, MD (+86 13911172565, yongjunwang111@aliyun.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The major cardiovascular events (time frame: A median of 2 years follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07242599, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.